Revolutionising drug development: unveiling the synergy of AI’s regulatory harmony in shaping the future of biopharmaceutical progress


In this article, we consider how artificial intelligence (AI) is not merely an auxiliary tool but an essential partner in the biopharmaceutical industry’s pursuit of innovative therapies and life-changing medications. It has the potential to bring about a paradigm shift in the way that novel treatments are discovered and delivered. However, proactive measures, including establishing clear standards for data quality and collaborative efforts in regulatory frameworks, are pivotal steps toward realising the full benefits of AI in biopharmaceuticals.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

Members login

Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.



Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

  • Create your own library to save your favourite content.
  • Sign up for Regulatory Rapporteur email newsletters.
Create a free account


TOPRA membership

Become a TOPRA member and join our global community of regulatory affairs professionals.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.
Become a member